106792-41-0

Basic information

• Product Name: 6-(TERT-BUTYLDIMETHYLSILYLOXY)-INDOLE
• Synonyms: 6-(TERT-BUTYLDIMETHYLSILYLOXY)-INDOLE;6-[(tert-Butyldimethylsilyl)oxy]-1H-indole
• CAS NO: 106792-41-0
• Molecular Formula: C₁₄H₂₁NOSi
• Molecular Weight: 247.41
• Mol File: 106792-41-0.mol

Chemical Properties

• Boiling Point: 318.8±15.0 °C(Predicted)
• Appearance: /
• Density: 1.013±0.06 g/cm3(Predicted)
• PKA: 17.26±0.30(Predicted)
• CAS DataBase Reference: 6-(TERT-BUTYLDIMETHYLSILYLOXY)-INDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(TERT-BUTYLDIMETHYLSILYLOXY)-INDOLE(106792-41-0)
• EPA Substance Registry System: 6-(TERT-BUTYLDIMETHYLSILYLOXY)-INDOLE(106792-41-0)

Safety Data

• Hazardous Substances Data: 106792-41-0(Hazardous Substances Data)

Upstream product

• 15903-94-3 6-benzyloxy-1H-indole 
• 3189-13-7 6-methoxylindole 
• 2380-86-1 6-hydroxy-1H-indole 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 69739-34-0 t-butyldimethylsiyl triflate 

Downstream Products

• 870098-73-0 6-(tert-butyldimethylsiloxymethyl)-2-[6-(4-hydroxy-3,5-dimethyl-phenyl)-3-methoxy-pyridazin-4-yl]-indole-1-carboxylic acid tert-butyl ester 
• 1428972-79-5 1-(6-((tert-butyldimethylsilyl)oxy)-1H-indol-3-yl)-2-chloro-2-phenylethanone 
• 1428969-27-0 1-(6-hydroxy-1H-indol-3-yl)-2-((3-methoxyphenyl)amino)-2-phenylethanone 
• 1428972-80-8 1-(6-((tert-butyldimethylsilyl)oxy)-1H-indol-3-yl)-2-((3-methoxyphenyl)amino)-2-phenylethanone 
• 848357-99-3 6-(tert-butyldimethylsilanyloxy)indole-1-carboxylic acid tert-butyl ester 2-boronic acid 
• 854638-56-5 6-(tert-butyldimethylsilanyloxy)indole-1-carboxylic acid tert-butyl ester 
• 1310716-96-1 C₂₇H₂₉NO₃Si 
• 1207869-48-4 C₂₁H₁₅NO₃ 
• 613679-62-2 BPR₀L₀₈₂ 
• 753488-91-4 [6-(tert-butyl-dimethyl-silanyloxy)-1H-indol-3-yl]-(3,4,5-trimethoxy-phenyl)-methanone 

Relevant articles and documents

VIRAL REPLICATION INHIBITORS

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

Indolyne experimental and computational studies: Synthetic applications and origins of selectivities of nucleophilic additions

Efficient syntheses of 4,5-, 5,6-, and 6,7-indolyne precursors beginning from commercially available hydroxyindole derivatives are reported. The synthetic routes are versatile and allow access to indolyne precursors that remain unsubstituted on the pyrrole ring. Indolynes can be generated under mild fluoride-mediated conditions, trapped by a variety of nucleophilic reagents, and used to access a number of novel substituted indoles. Nucleophilic addition reactions to indolynes proceed with varying degrees of regioselectivity; distortion energies control regioselectivity and provide a simple model to predict the regioselectivity in the nucleophilic additions to indolynes and other unsymmetrical arynes. This model has led to the design of a substituted 4,5-indolyne that exhibits enhanced nucleophilic regioselectivity.

Novel pyridazinone derivatives as inhibitors of CDK2

The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R1 and R2 given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2)

PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS

The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R1 and R2 given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. Formula (I) These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK-15 30 (glycogen synthase kinase-3?).

Novel organophosphorus derivatives of indazoles and use thereof as medicinal products

The present invention relates in particular to novel chemical compounds, particularly to novel organophosphorus derivatives of indazoles, to the compositions containing them, and to the use thereof as medicinal products for treating cancers.

Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents

The synthesis and study of the structure-activity relationships of two new classes of synthetic antitubulin compounds based on 1-aroylindole and 3-aroylindole skeletons are described. Lead compounds 3, 10, and 14 displayed potent cytotoxicities with ICsu

3-(2-(3-Pyridinyl)thiazolidin-4-oyl)indoles, a Novel Series of Platelet Activating Factor Antagonists

(2RS,4R)-3-(2-(3-pyridinyl)thiazolidin-4-oyl)indoles represent a new class of potent, orally active antagonists of platelet activating factor (PAF). The compounds were prepared by acylation of the magnesium or zinc salts of substituted indoles with (2RS,4R)-2-(3-pyridinyl)-3-(tert-butoxycarbonyl)thiazolidin-4-oyl chloride. The 3-acylindole moiety functions as a hydrolytically stabilized and conformationally restricted anilide replacement, which imparts a considerable boost in potency to the series. Structure-activity relationships observed for substitution on the indole ring system are discussed. Members of the series compare favorably with other reported PAF antagonists.